The study from Norway used 42 Gy in 3 weeks. CONVERT had gr 3 or 4 esophagitis in 18% regardless of QD66 or BID45/3wk. Since I am stuck on 45Gy, I use 45 Gy in 3 wks for incapable, refuse BID or ED-SCLC.

Two hypofractionated regimens were mentioned, 40/15 and 42/15; I will confine my calculations to 42/15.Biologically effective dose calculations w/(acute) time corrections follow. For both 45/30 bid and 42/15 we will assume (on average) 19 elapsed treatment days (weekdays+weekends) for both regimens....

In short (and in my opinion), yes, although clear data on this in a modern patient cohort is limited.While CONVERT has given us data to support qd (conventionally fractionated) or bid, there is little to guide us on hypofx vs. bid.There was a randomized phase II trial published in 2016, which compar...